Skip to Content

Carbon Nanotube Transistors Orders of Magnitude Better at Spotting Cancer, Say Bioengineers

Arrays of carbon-nanotube transistors can detect prostate cancer with a much higher sensitivity than conventional techniques.

The early detection of many diseases dramatically improves prognoses. Prostate cancer is a case in point, with a 60 to 90 percent long-term survival rate in patients who are diagnosed at an early stage.

The problem, of course, is making such a diagnosis quickly and accurately. The standard test is for prostate-specific antigen, which is produced by a cancerous prostate in relatively high quantities.

However, the trouble with PSA tests is they produce a significant number of false positives and false negatives. So some healthy men end up undergoing invasive tests while others with the disease go undetected.

There is another biomarker of the disease known as osteopontin, or OPN. The state-of-the art technique for spotting this is known as ELISA. In this test, OPN from a sample is attached to a surface. The surface is washed with OPN-binding antibodies, which are themselves attached to colour-changing enzymes. If these antibodies bond with the OPN, the colour change can be easily detected.  

But while this technique is sensitive, it is relatively time-consuming and difficult to use to quantify the amount of OPN.

So more sensitive and accurate techniques are highly sought after. Today, Mitchell Lerner at the University of Pennsylvania and a few buddies reveal just such a technique that uses an array of carbon nanotube transistors on a silicon chip to detect antigens such as OPN.

The trick they’ve perfected is a way of attaching an OPN-binding antibody to the carbon nanotube in each transistor. The electronic characteristics of the antibody-nanotube transistor can then be easily measured by the on-chip electronics.

When the chip is immersed in a sample, the OPN binds to the antibodies connected to the nanotubes, and this changes the electronic characteristics of the transistor. So measuring the current and voltage through each transistor is an accurate way of measuring how much OPN there is in the sample.

Lerner and co say their device can detect OPN at concentrations of 1 picogram per millilitre. That’s a concentration three orders of magnitude weaker than ELISA can manage.

And by replacing the OPN-binding antibody with molecules sensitive to other antigens, the carbon nanotube transistors can be made sensitive to other diseases. Lerner and co say they have successfully used the technique to detect Lyme disease and salmonella. 

That’s impressive work that has the potential to improve the diagnosis and detection of many diseases and pathogens. Of course, more work is needed to characterise the behaviour of these chips and in particular the circumstances in which they might give false positives or negatives.  But in the meantime, expect to hear more about them.

Refs: 

arxiv.org/abs/1302.2961: Detecting Lyme Disease Using Antibody-Functionalized SingleWalled Carbon Nanotube Transistors

arxiv.org/abs/1302.2959: A Carbon Nanotube Immunosensor for Salmonella

arxiv.org/abs/1302.2958: Hybrids of a Genetically Engineered Antibody and a Carbon Nanotube Transistor for Detection of Prostate Cancer

Keep Reading

Most Popular

Geoffrey Hinton tells us why he’s now scared of the tech he helped build

“I have suddenly switched my views on whether these things are going to be more intelligent than us.”

Meet the people who use Notion to plan their whole lives

The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.

Learning to code isn’t enough

Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.

Deep learning pioneer Geoffrey Hinton has quit Google

Hinton will be speaking at EmTech Digital on Wednesday.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.